TY - JOUR
T1 - Cell-modified bioprinted microspheres for vascular regeneration
AU - Shen, Jian
AU - Ji, Yongli
AU - Xie, Mingjun
AU - Zhao, Haiming
AU - Xuan, Wanling
AU - Yin, Li
AU - Yu, Xiaohua
AU - Xu, Fangfang
AU - Su, Shengan
AU - Nie, Jing
AU - Xie, Yao
AU - Gao, Qing
AU - Ma, Hong
AU - Ke, Xueying
AU - Shi, Zhenyu
AU - Fu, Jianzhong
AU - Liu, Zhenjie
AU - He, Yong
AU - Xiang, Meixiang
N1 - Funding Information:
This paper was sponsored by the National Natural Science Foundation of China (nos. 81670259 , 81870203 , U1909218 , 51622510 , 81970398 ).
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2020/7
Y1 - 2020/7
N2 - Cell therapy is a promising strategy in which living cells or cellular materials are delivered to treat a variety of diseases. Here, we developed an electrospray bioprinting method to rapidly generate cell-laden hydrogel microspheres, which limit the migration of the captured cells and provide an immunologically privileged microenvironment for cell survival in vivo. Currently, therapeutic angiogenesis aims to induce collateral vessel formation after limb ischemia. However, the clinical application of gene and cell therapy has been impeded by concerns regarding its inefficacy, as well as the associated risk of immunogenicity and oncogenicity. In this study, hydrogel microspheres encapsulating VEGF-overexpressing HEK293T cells showed good safety via subcutaneously injecting into male C57BL/6 mice. In addition, these cell-modified microspheres effectively promoted angiogenesis in a mouse hind-limb ischemia model. Therefore, we demonstrated the great therapeutic potential of this approach to induce angiogenesis in limb ischemia, indicating that bioprinting has a bright future in cell therapy.
AB - Cell therapy is a promising strategy in which living cells or cellular materials are delivered to treat a variety of diseases. Here, we developed an electrospray bioprinting method to rapidly generate cell-laden hydrogel microspheres, which limit the migration of the captured cells and provide an immunologically privileged microenvironment for cell survival in vivo. Currently, therapeutic angiogenesis aims to induce collateral vessel formation after limb ischemia. However, the clinical application of gene and cell therapy has been impeded by concerns regarding its inefficacy, as well as the associated risk of immunogenicity and oncogenicity. In this study, hydrogel microspheres encapsulating VEGF-overexpressing HEK293T cells showed good safety via subcutaneously injecting into male C57BL/6 mice. In addition, these cell-modified microspheres effectively promoted angiogenesis in a mouse hind-limb ischemia model. Therefore, we demonstrated the great therapeutic potential of this approach to induce angiogenesis in limb ischemia, indicating that bioprinting has a bright future in cell therapy.
KW - 3D bioprinting
KW - Cell therapy
KW - Therapeutic angiogenesis
KW - VEGF control release
UR - http://www.scopus.com/inward/record.url?scp=85083890472&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083890472&partnerID=8YFLogxK
U2 - 10.1016/j.msec.2020.110896
DO - 10.1016/j.msec.2020.110896
M3 - Article
C2 - 32409053
AN - SCOPUS:85083890472
SN - 0928-4931
VL - 112
JO - Materials Science and Engineering C
JF - Materials Science and Engineering C
M1 - 110896
ER -